For the Inventor, By the Inventor

Enter assignee name

Boulder, CO, United States of America

Biodesix, Inc.

USPTO Granted Patents = 51

% Expired Patents = 2.0

EPO Patents = 10

Trademarks = 17

Forward Citations = 319

Loading Chart...

Loading Chart...

33 inventors (with patents filed for the assignee):

Heinrich Röder (41 out of 41 patents)

Joanna Röder (25 out of 25 patents)

Julia Grigorieva (23 out of 23 patents)

4. Maxim Tsypin (20 out of 20 patents)

5. Carlos Oliveira (11 out of 11 patents)

6. Paul Edward Kearney (7 out of 23 patents)

7. Clive Hayward (7 out of 13 patents)

8. Xiao-Jun Li (7 out of 14 patents)

9. Arni Steingrimsson (6 out of 6 patents)

10. Kenneth Charles Fang (5 out of 11 patents)

11. Krista Meyer (5 out of 5 patents)

12. Senait Asmellash (5 out of 5 patents)

13. Kevin Sayers (3 out of 3 patents)

14. Caroline Maher (3 out of 3 patents)

15. Gary A Pestano (3 out of 17 patents)

Core Competencies:

Lung Cancer Diagnosis

Predictive Testing

Mass Spectrometry

Immunotherapy Benefit

Cancer Patient Classification

Biomarker Identification

EGFR Pathway Targeting

MALDI-TOF Technology

Blood Sample Analysis

Prognostic Testing

Antibody Drug Development

Clinical Diagnostics

51 patents: Sort by Forward Citations

1. 12603182 - Interpretation of machine learning classifications in clinical diagnostics using shapley values and uses thereof (2026-04-14),

2. 12247980 - Compositions, methods and kits for diagnosis of lung cancer (2025-03-11),

3. 12230398 - Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2025-02-18),

4. 12094587 - Apparatus and method for identification of primary immune resistance in cancer patients (2024-09-17),

5. 11913957 - Compositions, methods and kits for diagnosis of lung cancer (2024-02-27),

6. 11894147 - Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings (2024-02-06),

7. 11710539 - Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy (2023-07-25),

8. 11621057 - Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy (2023-04-04),

9. 11594403 - Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample (2023-02-28),

10. 11542340 - Antibodies targeting pulmonary nodule specific biomarkers and uses thereof (2023-01-03),

11. 11476003 - Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings (2022-10-18),

12. 11467167 - SRM methods in Alzheimer's disease and neurological disease assays (2022-10-11),

13. 11193935 - Compositions, methods and kits for diagnosis of lung cancer (2021-12-07),

14. 11150238 - Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups (2021-10-19),

15. 10950348 - Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2021-03-16),

Biodesix is a molecular diagnostics company that provides personalized medicine solutions for lung cancer. They offer blood-based tests and genomic profiling to aid in the diagnosis, treatment, and monitoring of patients with lung cancer. With a focus on precision medicine, Biodesix aims to improve patient outcomes through targeted therapies and individualized treatment plans.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

51 Patents

#30 in Boulder, CO

#133 in Colorado

#6,872 in US

#13,739 in the World

Boulder, CO, United States of America

Biodesix, Inc.

Forward Citations = 319

33 inventors:

Heinrich Röder (41 out of 41 patents)

Joanna Röder (25 out of 25 patents)

Julia Grigorieva (23 out of 23 patents)

4. Maxim Tsypin (20 out of 20 patents)

5. Carlos Oliveira (11 out of 11 patents)

Please report any incorrect information to [email protected]

Loading…